BCI Predictive Validation:
Trans-aTTom
Cancer
Index
Results from the Trans-aTTom Study
Trans-aTTom was the second prospective-retrospective study validating Breast Cancer Index® prediction and established level 1B evidence for BCI as a biomarker for extended endocrine therapy response.1,2
STUDY DESIGN
- 583 node positive patients with HR+, early-stage disease
- Randomized to 5 years of extended Tamoxifen (TAM) vs stopping after 5 years of primary adjuvant TAM
Risk Reduction And Absolute Benefit
BCI No (Not Likely to Benefit, H/I Low)
was associated with no significant benefit from extexnded TAM.
was associated with no significant benefit from extexnded TAM.
BCI Yes (Likely to Benefit, H/I High)
was associated with a 65% relative risk reduction and 10.2% absolute benefit.
was associated with a 65% relative risk reduction and 10.2% absolute benefit.
In the Trans-aTTom study, BCI effectively stratified patients into those who would or would not be likely to benefit from extended treatment.
Relative Benefit Of Extended Tamoxifen By BCI (H/I) Status: Trans-aTTom N+ Cases1
“Genomic classifiers that predict risk of late recurrence and/or benefit from extended endocrine therapy may help to further individualize the recommendation for extended aromatase inhibitor therapy.”3
- Eleftherios Mamounas, MD
References: 1. Bartlett et al. Annals of Oncol 2019 doi: 10.1093/annonc/mdz289. 2. Simon RM, et al. J Natl Cancer Inst 2009; 101(21):1446–1452. 3. Mamounas EP et al. NSABP B-42. GS4-01. SABCS 2019. Dec 12, 2019.
Eleftherios Mamounas, MD is an advisor for Biotheranostics, Inc.
Back to Top
